Trade Report: The Opko Health Inc. (OPK) Rating Reiterated by Jefferies Group

The Opko Health Inc. (OPK) Rating Reiterated by Jefferies Group

Jefferies Group restated their hold rating on shares of Opko Health Inc. (NYSE:OPK) in a research report sent to investors on Monday. They currently have a $10.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the company a buy rating in a report on Tuesday, August 9th. Standpoint Research raised their target price on Opko Health from $16.00 to $18.00 and gave the stock a buy rating in a report on Tuesday, June 21st. Oppenheimer Holdings Inc. reaffirmed a hold rating on shares of Opko Health in a report on Thursday, June 16th. Deutsche Bank AG decreased their target price on Opko Health from $11.00 to $10.00 and set a hold rating on the stock in a report on Thursday, June 16th. Finally, Zacks Investment Research raised Opko Health from a sell rating to a hold rating in a report on Tuesday, July 12th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $13.20.

Opko Health (NYSE:OPK) opened at 9.56 on Monday. The stock has a market capitalization of $5.26 billion and a PE ratio of 40.00. Opko Health has a 52-week low of $7.12 and a 52-week high of $11.85. The company’s 50-day moving average price is $10.07 and its 200 day moving average price is $10.08.

Opko Health (NYSE:OPK) last released its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $357.10 million for the quarter, compared to the consensus estimate of $324.11 million. Opko Health’s quarterly revenue was up 742.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) earnings per share. Equities analysts forecast that Opko Health will post ($0.05) EPS for the current fiscal year.

In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, August 2nd. The stock was purchased at an average price of $9.88 per share, for a total transaction of $98,800.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $30,321,235.88. The acquisition was disclosed in a filing with the SEC, which is available through this link.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPK. Janus Capital Management LLC raised its position in Opko Health by 0.6% in the second quarter. Janus Capital Management LLC now owns 15,800 shares of the company’s stock valued at $148,000 after buying an additional 100 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in Opko Health by 1.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 22,945 shares of the company’s stock valued at $214,000 after buying an additional 261 shares in the last quarter. Gilman Hill Asset Management LLC raised its position in Opko Health by 0.6% in the second quarter. Gilman Hill Asset Management LLC now owns 46,661 shares of the company’s stock valued at $436,000 after buying an additional 298 shares in the last quarter. Fisher Asset Management LLC raised its position in Opko Health by 1.1% in the third quarter. Fisher Asset Management LLC now owns 38,229 shares of the company’s stock valued at $405,000 after buying an additional 403 shares in the last quarter. Finally, Capstone Asset Management Co. raised its position in Opko Health by 3.3% in the third quarter. Capstone Asset Management Co. now owns 16,216 shares of the company’s stock valued at $172,000 after buying an additional 520 shares in the last quarter.

Opko Health Company Profile

Related posts

Leave a Comment